Inhibiting macrophage proliferation suppresses atherosclerotic plaque inflammation

Science Advances

Volumn 1, Issue 3, 2015, Pages

  Tang, Jun ^a   Lobatto, Mark E ^a,b   Hassing, Laurien ^a,b   Van Der Staay, Susanne ^a,b   Van Rijs, Sarian M ^a,b   Calcagno, Claudia ^a   Braza, Mounia S ^a   Baxter, Samantha ^a   Fay, Francois ^a   Sanchez Gaytan, Brenda L ^a   Duivenvoorden, Raphaël ^b   Sager, Hendrik B ^c   Astudillo, Yaritzy M ^d   Leong, Wei ^a   Ramachandran, Sarayu ^a   Storm, Gert ^e,f   Pérez Medina, Carlos ^a   Reiner, Thomas ^g   Cormode, David P ^h   Strijkers, Gustav J ^b   Stroes, Erik S G ^b   Swirski, Filip K ^c   Nahrendorf, Matthias ^c   Fisher, Edward A ^d   Fayad, Zahi A ^a   Mulder, Willem J M ^a,b   more..

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UTRECHT UNIVERSITY   (Netherlands)

^f UNIVERSITY OF TWENTE   (Netherlands)

^g MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^h UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL DEATH; MACROPHAGES; NANOPARTICLES;

APOLIPOPROTEIN E; ATHEROSCLEROTIC PLAQUE; MACROPHAGE PROLIFERATION; RAPID REDUCTION; SHORT TERM; SIMVASTATIN; THERAPEUTIC BENEFITS; THERAPEUTIC TARGETS;

PATHOLOGY;

EID: 85041012598     PISSN: None     EISSN: 23752548     Source Type: Journal    
DOI: 10.1126/sciadv.1400223     Document Type: Article

References (51)

1. P. Libby, P. M. Ridker, G. K. Hansson, Progress and challenges in translating the biology of atherosclerosis. Nature 473, 317-325 (2011).
2. F. K. Swirski, M. Nahrendorf, Leukocyte behavior in atherosclerosis, myocardial infarction, and heart failure. Science 339, 161-166 (2013).
3. I. Tabas, C. K. Glass, Anti-inflammatory therapy in chronic disease: Challenges and opportunities. Science 339, 166-172 (2013).
4. K. J. Moore, F. J. Sheedy, E. A. Fisher, Macrophages in atherosclerosis: A dynamic balance. Nat Rev. Immunol. 13, 709-721 (2013).
5. I. Tabas, Macrophage death and defective inflammation resolution in atherosclerosis. Nat. Rev. Immunol. 10, 36-46 (2010).
6. S. Potteaux, E.L.Gautier,S. B.Hutchison, N.van Rooijen,D.J. Rader, M.J.Thomas,M.G.SorcThomas, G. J. Randolph, Suppressed monocyte recruitment drives macrophage removal from atherosclerotic plaques of Apoe-/- mice during disease regression. J. Clin. Invest. 121, 2025-2036 (2011).
7. F. Leuschner, P. Dutta, R. Gorbatov, T. I. Novobrantseva, J. S. Donahoe, G. Courties, K. M. Lee, J. I. Kim, J. F. Markmann, B. Marinelli, P. Panizzi, W. W. Lee, Y. Iwamoto, S. Milstein, H. Epstein-Barash, W. Cantley, J. Wong, V. Cortez-Retamozo, A. Newton, K. Love, P. Libby, M. J. Pittet, F. K. Swirski, V. Koteliansky, R. Langer, R. Weissleder, D. G. Anderson, M. Nahrendorf, Therapeutic siRNA silencing in inflammatory monocytes in mice. Nat. Biotechnol. 29,1005-1010 (2011).
8. T. A. Seimon, Y. Wang, S. Han, T. Senokuchi, D. M. Schrijvers, G. Kuriakose, A. R. Tall, I. A. Tabas, Macrophage deficiency of p38a MAPK promotes apoptosis and plaque necrosis in advanced atherosclerotic lesions in mice. J. Clin. Invest. 119, 886-898 (2009).
9. J. R. McCarthy, E. Korngold, R. Weissleder, F. a Jaffer, A light-activated theranostic nano-agent for targeted macrophage ablation in inflammatory atherosclerosis. Small 6, 2041-2049 (2010).
10. J.E. Feig, Y. Shang, N. Rotllan, Y. Vengrenyuk, C. Wu, R. Shamir, LP. Torra, C. Fernandez-Hernando, E. A. Fisher, M.J. Garabedian, Statins promote the regression of atherosclerosis via activation of the CCR7-dependent emigration pathway in macrophages. PLOS One 6, e28534 (2011).
11. S.J.Jenkins, D. Ruckerl, P. C. Cook, L. H.Jones, F. D. Finkelman, N.van Rooijen, A. S. MacDonald, J. E. Allen, Local macrophage proliferation, rather than recruitment from the blood, is a signature of TH2 inflammation. Science 332, 1284-1288 (2011).
12. D. Hashimoto, A. Chow, C. Noizat, P. Teo, M. B. Beasley, M. Leboeuf, C D. Becker, P. See, J. Price, D. Lucas, M. Greter, A. Mortha, S. W. Boyer, E. C Forsberg, M.Tanaka, N. van Rooijen, A. Garcfa-Sastre, E. R. Stanley, F. Ginhoux, P. S. Frenette, M. Merad, Tissue-resident macrophages self-maintain locally throughout adult life with minimal contribution from circulating monocytes. Immunity 38, 792-804 (2013).
13. S. Yona, K. W. Kim, Y. Wolf, A. Mildner, D. Varol, M. Breker, D. Strauss-Ayali, S. Viukov, M. Guilliams, A. Misharin, D. A. Hume, H. Perlman, B. Malissen, E. Zelzer, S. Jung, Fate mapping reveals origins and dynamics of monocytes and tissue macrophages under homeostasis. Immunity 38, 79-91 (2013).
14. C. S. Robbins, I. Hilgendorf, G. F. Weber, I. Theurl, Y. Iwamoto, J. L. Figueiredo, R. Gorbatov, G. KSukhova, L. M. Gerhardt, D. Smyth, C. C. Zavitz, E. A. Shikatani, M. Parsons, N. van Rooijen, H. Y. Lin, M. Husain, P. Libby, M. Nahrendorf, R. Weissleder, F. K. Swirski, Local proliferation dominates lesional macrophage accumulation in atherosclerosis. Nat. MedA 9,1166-1172 (2013).
15. M. S. Brown, J. L. Goldstein, Multivalent feedback regulation of HMG CoA reductase, a control mechanism coordinating isoprenoid synthesis and cell growth. J. Lipid Res. 21,505-517 (1980).
16. M. K. Jain, P. M. Ridker, Anti-inflammatory effects of statins: Clinical evidence and basic mechanisms. Nat. Rev. Drug Discov. 4, 977-987 (2005).
17. M. J. Campbell, L. J. Esserman, Y. Zhou, M. Shoemaker, M. Lobo, E. Borman, F. Baehner, A. S. Kumar, K. Adduci, C. Marx, E. F. Petricoin, L. A. Liotta, M. Winters, S. Benz, C. C. Benz, Breast cancer growth prevention by statins. Cancer Res. 66, 8707-8714 (2006).
18. S. Kotamraju, C. L. Williams, C. L. Willams, B. Kalyanaraman, Statin-induced breast cancer cell death: Role of inducible nitric oxide and arginase-dependent pathways. Cancer Res. 67, 7386-7394 (2007).
19. Y. C. Lin, C. H. Chiang, L. T. Chang, C. K. Sun, S. Leu, P. L. Shao, M. C. Hsieh, T. H. Tsai, S. Chua, S. Y. Chung, Y. H. Kao, H. K. Yip, Simvastatin attenuates the additive effects of TNF-α and IL-18 on the connexin 43 up-regulation and over-proliferation of cultured aortic smooth muscle cells. Cytokine 62, 341-351 (2013).
20. T. Senokuchi, T. Matsumura, M. Sakai, M. Yano, T. Taguchi, T. Matsuo, K. Sonoda, D. Kukidome, K. Imoto, T. Nishikawa, S. Kim-Mitsuyama, Y. Takuwa, E. Araki, Statins suppress oxidized low density lipoprotein-induced macrophage proliferation by inactivation of the small G protein-p38 MAPK pathway. J. Biol. Chem. 280, 6627-6633 (2005).
21. R. Duivenvoorden, J. Tang, D. P. Cormode, A. J. Mieszawska, D. Izquierdo-Garcia, C. Ozcan, M. J. Otten, N. Zaidi, M. E. Lobatto, S. M. van Rijs, B. Priem, E. L. Kuan, C. Martel, EJ. Hewing, H. Sager, M. Nahrendorf, G. J. Randolph, E. S. Stroes, V. Fuster, E. A. Fisher, Z. A. Fayad, W. J. Mulder, A statin-loaded reconstituted high-density lipoprotein nanoparticle inhibits atherosclerotic plaque inflammation. Nat. Commun. 5, 3065 (2014).
22. P. Dutta, G. Courties, Y. Wei, F. Leuschner, R. Gorbatov, C. S. Robbins, Y. Iwamoto, B. Thompson, A. L. Carlson, T. Heidt, M. D. Majmudar, F. Lasitschka, M. Etzrodt, P. Waterman, M. T. Waring, A. T. Chicoine, A. M. van der Laan, H. W. Niessen, J. J. Piek, B. B. Rubin, J. Butany, J. R. Stone, H. A. Katus, S. A. Murphy, D. A. Morrow, M. S. Sabatine, C. Vinegoni, M. A. Moskowitz, M. J. Pittet, P. Libby, C. P. Lin, F. K. Swirski, R. Weissleder, M. Nahrendorf, Myocardial infarction accelerates atherosclerosis. Nature 487, 325-329 (2012).
23. T. Heidt, H. B. Sager, G. Courties, P. Dutta, Y. Iwamoto, A. Zaltsman, C. von Zur Muhlen, C. Bode, G. L. Fricchione, J. Denninger, C. P. Lin, C. Vinegoni, P. Libby, F. K. Swirski, R. Weissleder, M. Nahrendorf, Chronic variable stress activates hematopoietic stem cells. Nat. Med. 20, 754-758 (2014).
24. E. J. Freireich, E. A. Gehan, D. P. Rail, L. H. Schmidt, H. E. Skipper, Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother. Rep. 50, 219-244 (1966).
25. A. Phinikaridou, M. E. Andia, A. Protti, A. Indermuehle, A. Shah, A. Smith, A. Warley, R. M. Botnar, Noninvasive magnetic resonance imaging evaluation of endothelial permeability in murine atherosclerosis using an albumin-binding contrast agent. Circulation 126, 707-719 (2012).
26. A. Phinikaridou, M. E. Andia, G. Passacquale, A. Ferro, R. M. Botnar, Noninvasive MRI monitoring of the effect of interventions on endothelial permeability in murine atherosclerosis using an albumin-binding contrast agent. J. Am. Heart Assoc. 2, e000402 (2013).
27. G. Courties, T. Heidt, M. Sebas, Y. Iwamoto, D. Jeon, J. Truelove, B. Tricot, G. Wojtkiewicz, P. Dutta, H. B. Sager, A. Borodovsky, T. Novobrantseva, B. Klebanov, K. Fitzgerald, D. G. Anderson, P. Libby, F. K. Swirski, R. Weissleder, M. Nahrendorf, In vivo silencing of the transcription factor IRF5 reprograms the macrophage phenotype and improves infarct healing. J. Am. Coll. Cardiol. 63, 1556-1566 (2014).
28. J. E. Feig, S. Parathath, J. X. Rong, S. L. Mick, Y. Vengrenyuk, L. Grauer, S. G. Young, E. A. Fisher, Reversal of hyperlipidemia with a genetic switch favorably affects the content and inflammatory state of macrophages in atherosclerotic plaques. Circulation 123, 989-998 (2011).
29. G.W. Stone, A. Maehara, A.J. Lansky, B. de Bruyne, E. Cristea,G. S. Mintz, R. Mehran,J. McPherson, N. Farhat, S. P. Marso, H. Parise, B. Templin, R. White, Z. Zhang, P. W. Serruys; PROSPECT Investigators, A prospective natural-history study of coronary atherosclerosis. N. Engl. J. Med. 364, 226-235(2011).
30. K. K. Ray, C. P. Cannon, C. H. McCabe, R. Cairns, A. M. Tonkin, F. M. Sacks, G. Jackson, E. Braunwald; PROVE IT-TIMI 22 Investigators, Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: Results from the PROVE IT-TIMI 22 trial. J. Am. Coll. Cardiol. 46, 1405-1410 (2005).
31. I. Gregersen, M. Skjelland, S. Holm, K. B. Holven, K. Krogh-Sorensen, D. Russell, E. T. Askevold, C. P. Dahl, S. Orn, L. Gullestad, T. E. Mollnes, T. Ueland, P. Aukrust, B. Halvorsen, Increased systemic and local interleukin 9 levels in patients with carotid and coronary atherosclerosis. PLOS One 8, e72769 (2013).
32. J. L. Goldstein, M. S. Brown, Regulation of the mevalonate pathway. Nature 343, 425-430 (1990).
33. J. Greenwood, L. Steinman, S. S. Zamvil, Statin therapy and autoimmune disease: From protein prenylation to immunomodulation. Nat. Rev. Immunol. 6, 358-370 (2006).
34. M.-F. Demierre, P. D. R. Higgins, S. B. Gruber, E. Hawk, S. M. Lippman, Statins and cancer prevention. Nat. Rev. Cancer 5, 930-942 (2005).
35. S. Katsuki, T. Matoba, S. Nakashiro, K. Sato, J. Koga, K. Nakano, Y. Nakano, S. Egusa, K. Sunagawa, K. Egashira, Nanoparticle-mediated delivery of pravastatin inhibits atherosclerotic plaque destabilization/rupture in mice by regulating the recruitment of inflammatory monocytes. Circulation 129, 896-906 (2014).
36. M. A. Hernandez-Presa, M. Ortego, J. Tuhon, J. L. Martfn-Ventura, S. Mas, L. M. Blanco-Colio, C. Aparicio, L. Ortega, J. Gomez-Gerique, F. Vivanco, J. Egido, Simvastatin reduces NF-kB activity in peripheral mononuclear and in plaque cells of rabbit atheroma more markedly than lipid lowering diet. Cardiovasc. Res. 57, 168-177 (2003).
37. M. Aikawa, E. Rabkin, S. Sugiyama, S.J. Voglic, Y. Fukumoto, Y. Furukawa, M. Shiomi, F.J. Schoen, P. Libby, An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation 103, 276-283 (2001).
38. D. P. Cormode, T.Skajaa, M. M. van Schooneveld, R. Koole, P. Jarzyna, M. E. Lobatto, C. Calcagno, A. Barazza, R. E. Gordon, P. Zanzonico, E. A. Fisher, Z. A. Fayad, W. J. Mulder, Nanocrystal core high-density lipoproteins: A multimodality contrast agent platform. Nano Lett. 8, 3715-3723 (2008).
39. Y. Kim, F. Fay, D. P. Cormode, B. L. Sanchez-Gaytan, J. Tang, E. J. Hennessy, M. Ma, K. Moore, O. C. Farokhzad, E. A. Fisher, W. J. Mulder, R. Langer, Z. A. Fayad, Single step reconstitution of multifunctional high-density I i pop rote in -derived nanomaterials using microfluidics. ACS Nano 7, 9975-9983 (2013).
40. K. C. Briley-Saebo, S. Geninatti-Crich, D. P. Cormode, A. Barazza, W. J. Mulder, W. Chen, G. B. Giovenzana, E. A. Fisher, S. Aime, Z. A. Fayad, High-relaxivity gadolinium-modified high-density lipoproteins as magnetic resonance imaging contrast agents. J. Phys. Chem. B 113, 6283-6289 (2009).
41. L. Chen, G. Yang, J. Monslow, L. Todd, D. P. Cormode, J. Tang, G. R. Grant, J. H. DeLong, S. Y. Tang, J. A. Lawson, E. Pure, G. A. Fitzgerald, Myeloid cell microsomal prostaglandin E synthase-1 fosters atherogenesis in mice. Proc. Natl. Acad. Sci. U.S.A. 111, 6828-6833 (2014).
42. P. K. Shah, J. Yano, O. Reyes, K. Y. Chyu, S. Kaul, C. L. Bisgaier, S. Drake, B. Cercek, High-dose recombinant apolipoprotein A-lMMano mobilizes tissue cholesterol and rapidly reduces plaque lipid and macrophage content in apolipoprotein E-deficient mice. Potential implications for acute plaque stabilization. Circulation 103, 3047-3050 (2001).
43. S. E. Nissen, T. Tsunoda, E. M. Tuzcu, P. Schoenhagen, C. J. Cooper, M. Yasin, G. M. Eaton, M.A. Lauer, W.S.Sheldon, C. L. Grines,S. Halpern, T. Crowe, J. C. Blankenship, R. Kerensky, Effect of recombinant ApoA-l Milano on coronary atherosclerosis in patients with acute coronary syndromes: A randomized controlled trial. JAMA 290, 2292-2300 (2003).
44. J. C. Tardif, J. Gregoire, P. L. L'Allier, R. Ibrahim, J. Lesperance, T. M. Heinonen, S. Kouz, C. Berry, R. Basser, M. A. Lavoie, M. C. Guertin, J. Rodes-Cabau; Effect of rHDL on Atherosclerosis-Safety and Efficacy (ERASE) Investigators, Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: A randomized controlled trial. JAMA 297, 1675-1682 (2007).
45. D. J. Rader, G. K. Hovingh, HDL and cardiovascular disease. Lancet 384, 618-625 (2014).
46. Y. Han, J. Jing, S. Tu, F. Tian, H. Xue, W. Chen, J. Chen, J. H. Reiber, Y. Chen, ST elevation acute myocardial infarction accelerates non-culprit coronary lesion atherosclerosis. Int. J. Cardiovasc. Imaging 30, 253-261 (2014).
47. S. Katsuda, M. D. Coltrera, R. Ross, A. M. Gown, Human atherosclerosis. IV. Immuno-cytochemical analysis of cell activation and proliferation in lesions of young adults. Am. J. Pathol. 142, 1787-1793 (1993).
48. M. D. Rekhter, D. Gordon, Active proliferation of different cell types, including lymphocytes, in human atherosclerotic plaques. Am. J. Pathol. 147, 668-677 (1995).
49. E. Lutgens, E. D. de Muinck, P. J. Kitslaar, J. H. Tordoir, H. J. Wellens, M. J. Daemen, Biphasic pattern of cell turnover characterizes the progression from fatty streaks to ruptured human atherosclerotic plaques. Cardiovasc. Res. 41, 473-479 (1999).
50. C. Perez-Medina, D. Abdel-Atti, Y. Zhang, V. A. Longo, C. P. Irwin, T. Binderup, J. Ruiz-Cabello, Z. A. Fayad, J. S. Lewis, W.J. Mulder, T. Reiner, A modular labeling strategy for in vivo PET and near-infrared fluorescence imaging of nanoparticle tumor targeting. J. Nucl. Med. 55,1706-1711 (2014).
51. J. A. Finegold, P. Asaria, D. P. Francis, Mortality from ischaemic heart disease by country, region, and age: Statistics from World Health Organisation and United Nations. Int. J. Cardiol. 168, 934-945 (2013).